key: cord-0874800-uay439ql
authors: Mallik, Ritwika; Chowdhury, Tahseen A.
title: Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future
date: 2022-03-04
journal: Ther Adv Endocrinol Metab
DOI: 10.1177/20420188221081601
sha: 679cd244659b0e2c466547c6309199756901b389
doc_id: 874800
cord_uid: uay439ql

Diabetic kidney disease (DKD) is a leading cause of morbidity and mortality among people living with diabetes, and is one of the most important causes of end stage renal disease worldwide. In order to reduce progression of DKD, important management goals include treatment of hypertension, glycaemia and control of cardiovascular risk factors such as lipids, diet, smoking and exercise. Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers has an established role in prevention of progression of DKD. A number of other agents such as endothelin-1 receptor antagonists and bardoxolone have had disappointing results. Recent studies have, however, suggested that newer antidiabetic agents such as sodium-glucose transporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 analogues have specific beneficial effects in patients with DKD. Indeed most recent guidance suggest that SGLT-2i drugs should be used early in DKD, irrespective of glucose control. A number of pathways are hypothesised for the development and progression of DKD, and have opened up a number of newer potential therapeutic targets. This article aims to discuss management of DKD with respect to seminal trials from the past, more recent trials informing the present and potential new therapeutic options that may be available in the future.

In 2015, 415 million people worldwide were estimated to have diabetes mellitus; by 2040 is it suggested that this will rise to 642 million. 1 A commensurate rise in renal disease associated with diabetes has been seen. Around 3% of people with newly diagnosed diabetes have evidence of diabetic kidney disease (DKD). The condition is the single most common cause of end stage renal disease (ESRD) in developed countries, accounting for 25-45% of all patients entering dialysis programmes. 2 Between 1990 and 2012, the number of deaths attributed to DKD rose by 94%. 3 DKD is a major cause of mortality and morbidity in people with diabetes. The condition is characterised by the presence of progressive renal impairment and the detection of albuminuria. In addition to renal morbidity, people who develop DKD suffer an increased cardiovascular mortality and morbidity, and well as increased risk of other microvascular complications. 4 In this review, we outline the pharmacotherapy of DKD especially in Type 2 diabetes (T2D), focussing on well-established evidence based therapies, newly identified agents and possible future interventions.

Definition of DKD and screening DKD is a clinical diagnosis made based on the presence of albuminuria and/or reduced eGFR, in a person with an established diagnosis of Type 1 diabetes (T1D) or T2D. 5 Table 1 outlines the various methods of measuring albuminuria and their normal ranges using the nomenclature recommended by the latest Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines. These refer to normal to mildly increased, moderately increased and severely increased albuminuria to replace normo, micro-and macroalbuminuria, respectively. 6 In clinical practice recommendations by American Diabetes Association (ADA), normal albumin creatinine ratio (ACR) is defined as < 30 mg/g, and high urinary albumin excretion as ⩾ 30 mg/g. 7 The most convenient screening method appears to be a single (preferably early morning) urine sent for ACR, and an estimated glomerular filtration rate (eGFR), taken at least annually. If urinary ACR is abnormal, it should be repeated to confirm. Arbitrary cut offs for albuminuria are described, although it is clear that the value is a continuous variable, and may have significant dayto-day differences in an individual person. 8 The presence of mildly elevated ACR, however, does appear to be an early precursor of progression to severely increased albuminuria in many patients, although some may regress to normal albumin excretion due to therapeutic intervention. 9 A broader term of chronic kidney disease (CKD) in people with diabetes is used to describe people with diabetes who have a reduced eGFR below 60 ml/min/1.73 m 2 , irrespective of cause. If albuminuria is not present is such patients, then DKD may be less likely, and alternative diagnoses should be considered. 10 CKD in the absence of albuminuria in an elderly person with diabetes is less likely to progress to ESRD. 11 Other reasons to consider non-diabetic renal disease in people with diabetes and CKD are the absence of retinopathy, rapid deterioration in renal function, active urinary sediment, nephrotic range albuminuria (ACR > 220 mg/mmol), or symptoms/signs of other systemic disease.

Risk factors for DKD are outlined in Table 2 . Risk factors amenable to intervention include blood pressure, dyslipidaemia, smoking, and hyperglycaemia.

Hyperglycaemia is an important risk factor for the development of DKD and occurs as a result of insulin resistance and/or decreased insulin production. Hyperglycaemia results in complex interplay of downstream signals and increase in reactive oxygen species (ROS) either directly by activation of ROS processes and impairment of antioxidant function, or indirectly via activation of aldose reductase and production of advanced glycation end products. Hyperglycaemia is also associated with insulin resistance, production of protein kinase C and transforming growth factor β which results in DKD. 12 Over 22 years of follow-up of the Diabetes Control and Complications Trial (DCCT) cohort, which compared intensive versus standard glucose control studied the effects of intensive glucose control on vascular outcome and concluded that intensive control reduced the incidence of combined macrovascular and microvascular events, primarily due to reduction in incidence of nephropathy. 15 By contrast, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study published at the same time noted that use of intensive glucose lowering therapy as compared to standard therapy was associated with increased mortality and did not significantly reduce major cardiovascular events. 16 There appears to be a concordance between the prevalence of retinopathy and renal dysfunction in patients with diabetes; in a study of 232 patients, retinopathy progression appeared to be associated with renal lesions and the development of end stage kidney disease ESRD. 17 In patients with T2D, diabetic retinopathy also appears to be a prognostic factor for the progression of CKD, hence may be a predictive tool of the clinical course of DKD. 18 Hypertension is a much stronger risk factor for the development and progression of DKD. In the UKPDS hypertension study, treated to a target of < 150/85 mmHg versus a standard target of < 180/105 mmHg led to a 37% risk reduction in microvascular complications. 19 Each 10 mmHg increase in blood pressure led to a 15% increase in risk of CKD stage 3 (eGFR < 60 ml/min/1.73 m 2 ), onset of albuminuria or doubling of serum creatinine. Figure 1 outlines the RAAS, and potential sites at which it may be inhibited for treatment of DKD.

The cornerstone of management of DKD involves treatment of hypertension, primarily using RAAS blocking agents such as angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs). ACEI promote sodium and water excretion by inhibition of aldosterone and also cause vasodilatation of renal arterioles, while ARBs cause sodium and water excretion by binding to angiotensin receptors. 20 There is strong randomised trial evidence that ACEI and ARBs delay the progression of DKD.

The Collaborative Study Group (CSG) Captopril Trial in 1993 demonstrated efficacy of captopril in patients with T1D and DKD, suggesting that captopril protected against deterioration in renal function in people with T1D, over and above its blood pressure lowering effect. 21 In patients with T1D and overt nephropathy, glomerular barrier size-selectivity progressively deteriorates with time and is effectively improved by ACEI. 22 By contrast, however, a prospective investigation in 2000 of the patients enrolled in the Ramipril Efficacy in Nephropathy (REIN) study, patients with T2D and nephropathy did not benefit significantly with ramipril; indeed renal function declined faster compared to use of other antihypertensives. 23 However, the Heart Outcome Prevention Evaluation (HOPE) study showed significant benefit of ramipril in cardiovascular mortality and morbidity, especially in people with T2D. 24 Further evidence for beneficial effects of ACEI in T2D was suggested in the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) in 2004, where use of trandolapril in patients with diabetes without albuminuria, prevented the onset of microalbuminuria. 25 Furthermore, the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial in 2008 concluded that ramipril did not improve cardiorenal outcomes during 3-year follow-up. 26 In the BENEDICT-B trial in 2011, in patients with T2D and microalbuminuria, trandolapril resulted in normoalbuminuria in half of the patients which translated into significant cardioprotection. 27 In normotensive diabetic nephropathy, a Bayesian network meta-analysis for ACEI or ARBs revealed monotherapy with enalapril seemed to be the most efficacious intervention for reduction of albuminuria. 28 In a meta-analysis on major cardiovascular 

Use of ARBs in T2D with DKD have shown even stronger evidence of benefit. In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study in 2001, use of losartan as compared to placebo was associated with a reduction in ESRD, doubling of serum creatinine, a 35% decrease in proteinuria, and reduction in the rate for hospitalisation for heart failure (hHF). 30 The Irbesartan Diabetic Nephropathy Trial (IDNT) trial in 2001 showed that irbesartan protected against the progression of diabetic nephropathy, and the renoprotective effect was also independent of the antihypertensive effect. 31 A further study in 2002, the MicroAlbuminuria Reduction with VALsartan (MARVAL) trial, showed that for a similar level of blood pressure reduction, valsartan lowered urine albumin excretion rate (UAER) more effectively than amlodipine. 32 Similarly, the Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATON) study in 2007 was set out to investigate the efficacy of telmisartan in preventing transition from incipient to overt nephropathy in Japanese patients with T2D. 33 There was a dose dependent beneficial effect of telmisartan in not only reducing transition of microalbuminuria to macroalbuminuria, but also induced remission of microalbuminuria. In patients with T2D and normoalbuminuria, The Randomised Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) study in 2011 suggested olmesartan delayed the onset of microalbuminuria. 34 In clinical practice, ACEI and ARBs are used interchangeably in DKD, although ARBs may be better tolerated in terms of cough and other adverse effects. 35 Overall, in patients with T2D and proteinuria found that ACEI/ARBs may reduce ESRD and slow the progression of nephropathy but do not demonstrate a decrease all-cause or cardiovascular mortality. 36 Combined ACEI and ARB therapy ACEI can be bypassed by chymases leading to increased angiotensin II production. In addition, ARBs do not completely block the RAAS. As single blockade does not completely block the RAAS, it has been hypothesised that 'dual blockade' might provide some benefits in DKD. 37 In the ONTARGET study in 2008, the combination of Telmisartan and Ramipril was associated with more adverse events without an increase in benefit as compared to monotherapy. 38 In DKD, dual blockade was able to reduce proteinuria compared with single agent blockade, but did not provide long-term renal benefit in the VA nephron D study in 2014, which was stopped early due to increased adverse events including hyperkalaemia and cardiorenal events. 39 A meta-analysis of 32 studies on the combination treatment of ACEI and ARB in diabetic nephropathy concluded that dual therapy reduced proteinuria but there was no additional benefit in reducing ESRD in severe cases and there was increased incidence of adverse reactions, hence should be used with caution in this group. 40 Increased adverse reactions of dual therapy has been a limiting factor their use. Risks may be mitigated by measures such as improved education regarding hyperkalaemia or use of potassium binders to reduce the risk of hyperkalaemia. Given that low-dose ACEI and ARBs leads to more effective RAAS blockade with fewer adverse events, and with the advent of new RAAS inhibitors, RCTs to re-evaluate the role of dual RAAS blockade for cardiorenal protection with individualised therapy should be considered. 41 The chymase inhibitor, fulacimstat has been tested to determine whether it would offer additional benefits over ACEI. In a randomised trial in patients with T2D and DKD, however, the drug did not reduce albuminuria as compared to placebo. 42

One of the rationales for developing direct renin inhibitors was to target the rate limiting step in the RAAS pathway. The ALTITUDE study evaluated the use of aliskiren in addition to RAAS blockade to reduce cardiovascular and renal events in patients with T2D and CKD, CVD or both was terminated prematurely. 43 There was no benefit seen in terms of cardiovascular or renal outcomes as compared to placebo, and a significant number of adverse effects such as hyperkalaemia, hypotension, and renal dysfunction occurred.

Hyporeninaemia may be seen in people with diabetes, and proponents for the use of DRIs in DKD suggest that identification of patients responsive to DRIs using plasma renin activity may be warranted, as this subgroup may benefit from DRI use. 44 A meta-analysis of the dual blockade of the RAAS in DKD suggested dual inhibition is superior to monotherapy for short-term indices such as reduction in blood pressure and urine protein excretion but did not translate to improvement in longer outcomes such as progression to ESRD, all-cause mortality or cardiovascular mortality. 45 

The benefits of ACEI and ARBs in CKD has been ascribed to reduction in systemic and intraglomerular blood pressure and proteinuria, but there has been increasing focus on benefits of reduction in aldosterone due to the deleterious effect of overactivation of mineralocorticoid receptors (MR) by aldosterone in kidney and heart disease ultimately resulting in inflammation and fibrosis. 46 Therapeutic Advances in Endocrinology and Metabolism 13 6 journals.sagepub.com/home/tae

It has been noted that after long term use of ACEI or ARB, 'aldosterone breakthrough' may occur, in which aldosterone levels may rise to pre-treatment levels. [47] [48] [49] In a study of patients with T1D and DKD on losartan, after 3 years the decline in eGFR was almost double in patients with aldosterone escape than without. 48 Aldosterone breakthrough may increase cardiovascular or renal mortality, and post hoc analysis of the AMADEO study (losArtan versus telMisArtan in hypertensive type-2 DiabEtic patients with Overt nephropathy) concluded that aldosterone breakthrough in T2D with DKD on ARB is a relatively frequent occurrence. 50 In the finerenone group, secondary CV outcomes were lower but hyperkalaemia related discontinuation was higher. Overall finerenone lowered risk of CKD progression and CV events. A further study by the same investigators found that finerenone reduced the risk of CV and renal failure outcomes in patients with and without a history of CVD as compared to placebo. 53 In the FIGARO-DKD study, fineronone therapy improved CV outcomes as compared to placebo in patients with T2D, CKD stages 2-4 with moderately elevated albuminuria or CKD stages 1 and 2 with severely elevated albuminuria. 54 Hence, finerenone may represent an important therapeutic option in DKD and non-diabetic kidney disease.

A wealth of cardiovascular outcome trials (CVOTs) in people with T2D and DKD have been published, and have informed clinical practice.

SGLT-2i block glucose reabsorption in the proximal renal tubule, thereby promoting glycosuria, reducing in plasma glucose and inducing weight loss. As renal function declines, however, less glucose is filtered leading to an attenuated glucose lowering effect in patients with CKD. 55 Based on these studies, canagliflozin and dapagliflozin are now licenced for use for renal and cardiovascular protection in DKD and can be initiated in patients with T2D and macroalbuminuria, and eGFR > 30 ml/min/1.73 m 2 (>15 ml/ min/1.73 m 2 for dapagliflozin) as add on to ACEI, irrespective of glucose control.

With regards to adverse effects, the commonest adverse event is genital mycotic infections, which may commonly occur early in treatment. 59 Urinary tract infections (UTIs) are less frequent. An important, but rare, adverse effect is that of euglycaemic ketoacidosis. 60 Careful patient education around 'sick day rules' (cessation of the drug during intercurrent illness), avoidance prior to surgery and avoidance of ketogenic diets is required. 61 Renoprotective effects of SGLT-2i are thought to be mediated by tubuloglomerular feedback, natriuresis and glucose induced osmotic diuresis which reduce intraglomerular pressure. 62 Cardiovascular outcome trials (CVOTs) have shown significant reduction in MACE in patients with T2D, and a meta-analysis of four key CVOTs (EMPAREG-OUTCOME, CANVAS, DECLARE, CREDENCE) indicate a major role of renal function in determining the extent of MACE prevention, where-in beneficial effects may be greater in patients with DKD. There may, therefore, be a case for early use of SGLT2i in order to slow progression of DKD and prevent MACE. 63 Although various studies have looked at renal outcomes, due to the heterogeneity in the endpoints it is important to unify major adverse renal events (MARE) which has been proposed and this can be used to design future clinical trial focussed on DKD. 64, 65 However, there remains a difficulty in building an evidence base for judicious use of certain classes of drugs in groups of patients at a low risk of adverse events, for whom a matched placebo group may not reach pre-specified end-points at a sufficient rate. A further network meta-analysis found that both groups reduced cardiovascular and renal outcomes with notable differences in risks and benefits. The absolute benefits of these drugs vary according to risk of cardiorenal outcomes and warrants individual risk assessment. 73 Given the different mechanism of action and beneficial effects seen with SGLT-2 inhibitors and GLP1-RA, the synergistic effects of using both groups has been explored. The long-term results of DURATION-8 (once weekly exenatide plus dapagliflozin) further demonstrates the efficacy and safety of combination therapy as seen with other studies where GLP1-RA was added to existing SGLT-2 inhibitors treatment such as AWARD-10 (dulaglutide plus SLGT-2 inhibitor), SUSTAIN-9 (semaglutide plus SGLT-2 inhibitor). 69 Further studies are required to Table 3 summarises some of the landmark clinical trials.

Darbepoietin Erythropoietin (EPO) is a glycoprotein hormone induced by hypoxia, is essential for erythropoiesis. In animal studies, EPO was identified as a direct renal protective factor, protecting kidney from hyperglycaemia induced damage and proteinuria. 77 Studies have alluded to EPO's extraerythropoietic actions including anti-apoptotic, anti-proliferative, anti-inflammatory and antiangiogenic effects in pancreatic islets. Recombinant human EPO is protective against development of diabetes in mouse models. 78 In another animal study, potential role of erythropoietin beta in reducing progression of DKD was suggested most likely due to the anti-inflammatory and anti-oxidative effect. 79 It has also been suggested that polymorphisms of the gene encoding EPO may be risk markers for DKD. 80 Darbepoietin alfa in patients with DKD and moderate anaemia was tested in the TREAT study. 81 The drug did not reduce the primary composite outcomes including ESRD, and was associated with an increased risk of stroke. 81 Bardoxolone Bardoxolone methyl is a therapeutic agent based on the scaffold of the natural product oleanolic acid. It attenuates inflammation by activating the Kelch-like ECH-associated protein 1 (Keap1)/ nuclear factor erythroid 2-related factor 2 (Nrf2) system. 82 Bardoxolone has been tested in DKD in the Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) trial, a phase 3 RCT in 2185 patients with T2D and stage 4 CKD. The trial was terminated due to increase in heart failure in patients randomised to bardoxolone. In the post hoc analysis, bardoxolone significantly decreased albuminuria. 83 A subsequent phase 2 study evaluated patients with DKD without any evidence of heart failure. Results were promising as bardoxolone significantly increased eGFR, with a significant intergroup difference of 6.64 ml/min/1.73 m 2 (p = 0.008). 84 It remains to be seen whether bardoxolone can be used safely in a subset of patients with DKD. A phase 3 study titled AYAME is evaluating bardoxolone in DKD stage 3 and 4 to evaluate the time of onset of a > 30% decrease in eGFR from baseline or end-stage kidney disease, with results expected in March 2022. 82 Endothelin a receptor antagonists Endothelin-1 (ET-1) is as a potent vasoactive factor which binds to two receptors, endothelin type A (ET A ) and type B (ET B ). CKD results in increased ET-1 production, which is implicated in deterioration of renal function due to promotion of pro-fibrotic pathways. 85 The ASCEND study, in which participants were assigned to avosentan, an ET A receptor antagonist (25-50 mg) or placebo in addition to ACEI or ARB, avosentan did significantly reduce albuminuria, but due to fluid overload in the avosentan group, the trial was prematurely terminated. 86 A subsequent study, the SONAR trial tested atrasentan, a ET A receptor antagonist in patients with T2D and DKD, on major renal outcomes. They used an enrichment design to exclude patients who developed fluid retention during the early period to minimise the risk of heart failure. Atrasentan was noted to be renoprotective in carefully selected patients without a history of severe peripheral oedema or admission due to heart failure with DKD, and showed a lower risk of doubling of serum creatinine or ESRD compared to placebo. The study was terminated, however, due to lower than expected event rate. 76 A recent systematic review and meta-analysis confirmed that selective ET A receptor antagonists (atrsentan and avosentan) but not bosentan (dual ET A/B receptor antagonist) effectively lowers albuminuria, blood pressure and improves lipid profiles along with composite endpoints in DKD. In Table 3 . Landmark clinical trials. 

There is emerging evidence on the role of bariatric and metabolic surgery in diabetes and CKD. The renoprotective effects of metabolic surgery in DKD appear independent of weight loss and improvements of glycaemia. 88 Various observational and RCTs seem to indicate that bariatric and metabolic surgery as an adjunct to medical therapy may decrease progression of DKD. 89 In terms of assessing the risk of incident microvascular complications, in a retrospective cohort study, bariatric and metabolic surgery was associated with decreased microvascular complication with adjusted hazard ratio for nephropathy being 0.63, 0.51-0.78, p < 0.001. 90 In the Microvascular Outcomes after Metabolic Surgery (MOMS) study in patients with T2D and class I obesity, at 2 years follow-up, Rouxen-Y gastric bypass (RYGB) was more effective than best medical treatment for achieving remission of albuminuria and stage G1 to G3 and A2 to A3 CKD. 91 Bariatric and metabolic surgery has the potential to slow or arrest DKD in obese patients and further studies are required including the effect of sleeve gastrectomy on DKD. OBESE-DKD (NCT04626323) is a phase 2 study to look into the safety and efficacy of RYGB surgery versus best medical treatment in the progression of DKD in obese patients with T2D.

Attempts to elucidate the pathogenic pathways in DKD continue, with a view to developing potential future interventions in DKD. Figure 2 outlines some of the hypothesised pathogenic mechanisms contributing to DKD, and possible interventions.

Hyperkalaemia is common in patients with CKD, especially those on RAAS inhibition. The occurrence of hyperkalaemia increases mortality within a day of the event. 92 Patiromer, a potassium-binding polymer, binds potassium through the gastrointestinal tract and increases faecal excretion of potassium. The AMETHYST-DN study showed that the use of patiromer twice daily in patients with DKD using ACEI, ARB or both with mild to moderate hyperkalaemia, resulted in statistically significant decreases in potassium level after 1 month of treatment. 93 Another potassium-binding resin that has garnered interest is sodium zirconium cyclosilicate (SZC), a highly selective cation exchanger. In a multicentre phase 3 trial in patients with hyperkalaemia (serum potassium 5.0-6.5 mmol/L) with sub group analyses for patients with diabetes, concluded that as compared to placebo, SZC resulted in significant reduction in potassium levels at 48 hours. 94 The advantage of such agents may be that they enable maximal RAAS blockade without discontinuation or due to hyperkalaemia. 95 Anti-fibrotic therapy Transforming growth factor beta-1 (TGF-β1) has been implicated in the pathogenesis of DKD. 96 It has been demonstrated that diabetes aggravates post-ischaemic renal fibrosis through persistent activation of TGF-β1 and sonic hedgehog (Shh) signalling, and insulin administration to control hyperglycaemia was not adequate to prevent progression of renal fibrosis. 97 Pirfenidone, an oral compound has been found to inhibit TGF-β1 production. In a small RCT of patients with DKD (eGFR 25-75 ml/min/1.73 m 2 ), pirfenidone was thought to show promising results. 98 Apart from its anti-fibrotic role, pirfenidone has been investigated for its action on gut microbiome diversity. A recent study hypothesised that changes in gut microbiota between diabetic and lean mice allow insights into role of gut microbes in DKD and potentially beneficial effects of pirfenidone. They concluded that gut microbial dysbiosis was partially reversed by long acting pirfenidone therapy. 99 Pentoxifylline is a nonspecific phosphodiesterase inhibitor is another anti-fibrotic agent known for its anti-inflammatory, anti-proliferative, anti-proteinuric and rheologic properties. Recent studies have investigated the role of pentoxifylline in Klotho signalling. 100 The PREDIAN trial was an open label RCT to determine whether pentoxifylline reduced albuminuria, in addition to RAAS blockade. Addition of pentoxifylline resulted in a smaller decrease in eGFR and reduction in albuminuria. 101 Larger, more definitive clinical trials are, however, required.

Advanced glycation end products (AGEs) are accelerated in diabetes, and the interaction of AGEs with receptors (RAGEs) activates an inflammatory cascade which is implicated in diabetes complications. 102 AGE-RAGE activation transduces pathways including PI3 K/AKT, MAPK/ERK, JAK2-STAT and NADPH oxidase provoking oxidative stress and inflammation in the renal cell. 103 Blocking AGE-RAGE signalling has been hypothesised as beneficial for DKD. Target cells include podocytes, mesangial, glomerular, endothelial, myofibroblastic cells and the Nrf2/ARE/GLO-1 pathway. 104 Limitations of synthetic and natural inhibitors of glycation include adverse effects and high cost, and lack of dose dependent standardisation for their safety and efficacy. 103 Pyridoxamine, a natural form of Vitamin B6 appears to be an effective inhibitor of AGE via journals.sagepub.com/home/tae 13 scavenging of methylglyoxal, and has been demonstrated to be beneficial in DKD in small studies, although further studies are needed to elucidate its role. 105 Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors Increased signalling of the JAK-STAT pathway is seen across the spectrum of DKD. Baricitinib, an oral selective reversible inhibitor of JAK 1 and 2 has been approved for use in rheumatoid arthritis 106 and is being evaluated in the management of severe Covid-19 infections. 107 A phase 2 RCT demonstrated that baricitinib reduced albuminuria in patients with DKD but was associated with a higher frequency of anaemia. 108 Nifuroxazide, an oral antibiotic for acute infectious diarrhoea is a potent and effective STAT3 inhibitor. In rats with diabetic-induced nephropathy, nifuroxazide mitigated the inflammatory burden and hindered the development and progression of diabetic nephropathy. 109

Adiponectin is an adipokine which improves insulin sensitivity. It also appears to have antiinflammatory, anti-oxidative and anti-fibrotic effects, and animal studies a beneficial effect of AdipoRon, an orally synthetic adiponectin receptor agonist in DKD. 110 AdipoRon, appears to be a safe and attractive treatment option in DKD. 111 Although there have been extensive preclinical studies, translation to clinical studies in humans is awaited.

Hydrogen sulphide (H2S) Impaired H2S signalling may play a role in pathogenesis of DKD. H2S may ameliorate RAAS activation, oxidative stress and inflammation and also reduce renal fibrosis. In-vitro an in-vivo experimental studies using H2S donors have demonstrated the beneficial effects of H2S donors on animal models of DKD. 112

Metallic organic framework (MOF), a novel class of crystalline porous material have been analysed at a nanoscale as therapeutic agents. Chromium containing MOF synthesised using nanochelating technology after 8 weeks of treatment in diabetic rats decreased insulin resistance and improved creatinine clearance. 113 Ethyl vanillin (EVA) Ethyl vanillin (EVA), an analogue of vanillin, is a common food additive and has antioxidant activity. In vivo and in vitro studies demonstrated that EVA may protect against DKD through inhibition of oxidative stress and apoptosis and the protective effect might be associated with the regulation of the activation of Nrf2. 114

MicroRNAs are small RNA molecules that are endogenously produced act as post-transcriptional suppressors of gene expression, and a review article discussed the use of different types of miRNAs as an anti-fibrotic treatment and role in DKD. 115 Although targeting fibrosis has been investigated as treatment for DKD, no approved therapeutic agent has been found but there is a potential for miRNA-based treatment in the future for DKD.

In mice, orally administered DMAPT (orally bioavailable analogue of parthenolide, a sesquiterpene lactone naturally present in plants) showed reduction in albuminuria, and significantly reduced glomerulosclerosis and tubulointerstitial fibrosis. 116 A review article summarised recent preclinical studies that had identified novel therapeutic renal and extra-renal targets in DKD including reduction of oxidative stress, inflammation, and haemodynamic changes. 117 The novel renal targets not discussed previously, included nicotinamide adenine dinucleotide phosphate oxidase 5 (NOX5), monocyte chemoattractant protein 1 -chemokine receptor 2 (MCP1-CCR2) and cannabinoid receptor type 1 and 2 (CB1R/CB2R), and extrarenal targets such as targeting mesenchymal stem cells (MSCs), extracellular vesicles (EVs) and microbiota were reviewed with strategies to improve translation of this research to humans.

Currently there are 34 phase 2 and 3 trials registered on clinicaltrials.gov on DKD/diabetic nephropathy that are recruiting, active but not recruiting and not yet recruiting patients. 118 To mention the ones not discussed previously, they include studies to investigate combination therapy of Dapagliflozin with AZD997 (a novel, selective mineralocorticoid receptor modulator) and another study with AZD5718 (a novel, potent, and selective FLAP inhibitor that inhibits the LTB 4 production) which are currently recruiting. A study involving CLBS201, a CD34+ cell investigational product for administration into the renal arteries, to improve or slow the decline of renal function in patients with T2D and CKD. Whether ezetimibe inhibits intestinal cholesterol absorption and affects albuminuria and kidney fat accumulation is being looked into in the DiaKidZ study and several studies with fenofibrate, a PPAR alpha agonist in patients with diabetic nephropathy and patients with type 1 diabetes T1D. N-Acetylcysteine (NAC) has anti-oxidative effects and there is a study focused on the possible ameliorating effect of NAC on diabeties nephropathy in patients with T2D. Inhibition of the TRPC5-Rac-1 pathway to prevent podocyte damage using a TRPC5 channel inhibitor in diabetic nephropathy. Roflumilast, a selective PDE 4 inhibitor with anti-inflammatory and anti-fibrotic effects, added to standard therapy for diabetic nephropathy to investigate its possible role in diabetic nephropathy is currently registered as a trial but not yet recruiting. Other studies on cotadutide (dual receptor agonist with balanced GLP1 and glucagon activity), and on mesenchymal stromal cells (MSCs) which might improve complications from diabetes is being investigated in NEPSTROM study in patients with T2D and CKD, and IL-33 mononoclonal antibody with dapagliflozin and a monoclonal antibody to block vascular endothelial growth factor-B (VEGF-B) in patients with DKD.

DKD remains an important microvascular complication of diabetes accounting for significant morbidity and mortality. Established management has been control of hypertension with ACEI/ ARB drugs, improvement of glucose control and management of cardiovascular risk factors. Recent pivotal studies have shifted the paradigm to use SGLT-2i drugs in all patients with T2D and established DKD. In addition, finerenone may be used in certain circumstances.

There is a huge amount of ongoing research into novel therapeutic agents in this condition, in the hope that they may offer further interventions to reduce the burden of DKD mortality and morbidity. 

IDF Diabetes Atlas

Epidemiology of diabetic kidney disease

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study

Kidney disease and increased mortality risk in type 2 diabetes

Brenner and Rector's the kidney

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease

Microvascular complications and foot care: standards of medical care in diabetes-2021

Diabetic kidney disease

Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus

Prevalence of nondiabetic renal disease in diabetic patients

Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicentre Study

Role of glucose metabolism and mitochondrial function in diabetic kidney disease

The diabetes control and complications trial/ epidemiology of diabetes interventions and complications study at 30 years: overview

10-year follow-up of intensive glucose control in type 2 diabetes

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Action to Control Cardiovascular Risk in Diabetes Study Group

Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease

The severity of diabetic retinopathy is an independent factor for the progression of diabetic nephropathy

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74

Diabetic kidney disease: diagnosis, treatment, and prevention

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury

The HOPE study (heart outcomes prevention evaluation)

Preventing microalbuminuria in type 2 diabetes

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

Effects of verapamil added-on trandolapril therapy inhypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial

Comparative proteinuria management of different angiotensinconverting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis

Effects of reninangiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials

Effects of losartan on renal and cardiovascular journals.sagepub.com/home/tae outcomes in patients with type 2 diabetes and nephropathy

Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes

What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment

Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with type 2 diabetes and proteinuria

Mitigating risk of aldosterone in diabetic kidney disease

Telmisartan, ramipril, or both in patients at high risk for vascular events

Combined angiotensin inhibition for the treatment of diabetic nephropathy

Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy

Dual blockade of the renin-angiotensin system: a strategy that should be reconsidered in cardiorenal diseases

Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Therapeutic renin inhibition in diabetic nephropathy: a review of the physiological evidence

Efficacy and safety of dual blockade of the renin-angiotensinaldosterone system in diabetic kidney disease: a meta-analysis

Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate

Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy

Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes

Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

Cardiovascular events with finerenone in kidney disease and type 2 diabetes

SGLT2 inhibitors and the diabetic kidney

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

Dapagliflozin in patients with chronic kidney disease

The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis

Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit

Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition

SGLT-2 inhibitor in people with type 2 diabetes: an educational resource for health professionals

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than preglomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney

Major adverse renal events (MARE): a proposal to unify renal endpoints

How to assess diabetic kidney disease progression? From albuminuria to GFR

Lixisenatide in patients with type 2 diabetes and acute coronary syndrome

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Liraglutide and renal outcomes in type 2 diabetes

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and metaanalysis of cardiovascular outcome trials

Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes

UK Prospective Diabetes Study (UKPDS) Group journals.sagepub.com/home/tae

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Targeting erythropoietin protects against proteinuria in type 2 diabetic patients and in zebrafish

Erythropoietin protects against diabetes through direct effects on pancreatic beta cells

Pleiotropic and renoprotective effects of erythropoietin beta on experimental diabetic nephropathy model

Associations between erythropoietin polymorphisms and risk of diabetic microvascular complications

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

Bardoxolone methyl: drug development for diabetic kidney disease

Effect of bardoxolone methyl on the urine albumin-tocreatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease

Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study)

Endothelin and endothelin antagonists in chronic kidney disease

Avosentan for overt diabetic nephropathy

Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials

Metabolic surgery improves renal injury independent of weight loss: a meta-analysis

Metabolic surgery to treat obesity in diabetic kidney disease, chronic kidney disease, and endstage kidney disease; what are the unanswered questions?

The impact of bariatric surgery on incident microvascular complications in patients with type 2 diabetes: a matched controlled populationbased retrospective cohort study

Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial

The frequency of hyperkalemia and its significance in chronic kidney disease

Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial

Sodium zirconium cyclosilicate in hyperkalemia

Effects and safety of a novel oral potassium-lowering drugsodium zirconium cyclosilicate for the treatment of hyperkalemia: a systematic review and meta-analysis

Transforming growth factor beta contributes to progressive diabetic nephropathy

Diabetes aggravates post-ischaemic renal fibrosis through persistent activation of TGF-β1 and Shh signalling

Pirfenidone for diabetic nephropathy

Gut microbial changes in diabetic db/db mice and recovery of microbial diversity upon pirfenidone treatment

Pentoxifylline for renal protection in diabetic kidney disease. a model of old drugs for new horizons

Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial

Advanced glycation end products and diabetic complications

Prevention of nonenzymatic glycosylation (glycation): implication in the treatment of diabetic complication

The development of maillard reaction, and advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling inhibitors as novel therapeutic strategies for patients with AGE-related diseases

How does pyridoxamine inhibit the formation of advanced glycation end products? The role of its primary antioxidant activity

Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis

Baricitinib plus remdesivir for hospitalized adults with covid-19

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial

Nifuroxazide, a STAT3 inhibitor, mitigates inflammatory burden and protects against diabetes-induced nephropathy in rats

The adiponectin receptor agonist AdipoRon ameliorates diabetic nephropathy in a model of type 2 diabetes

Mechanisms of adiponectin action: implication of adiponectin receptor agonism in diabetic kidney disease

Hydrogen sulfide: recent progression and perspectives for the treatment of diabetic nephropathy

Ameliorative effect of a nano chromium metalorganic framework on experimental diabetic chronic kidney disease

Ethyl vanillin protects against kidney injury in diabetic nephropathy by inhibiting oxidative stress and apoptosis

Potential targeting of renal fibrosis in diabetic kidney disease using MicroRNAs

Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease

The future of diabetic kidney disease management: what to expect from the experimental studies?

Visit SAGE journals online journals.sagepub.com/ home/tae

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The authors received no financial support for the research, authorship, and/or publication of this article.

Tahseen A. Chowdhury https://orcid.org/ 0000-0001-8878-2331 journals.sagepub.com/home/tae 17